Lung Cancer News

Adjuvant Statins Provide No Benefit in SCLC

Adjuvant Statins Provide No Benefit in SCLC

The addition of pravastatin to the first-line standard of care failed to provide benefit for patients with small-cell lung cancer (SCLC).

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).

NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Lung Cancer Screening Rates Remain Low Despite USPSTF Recommendations

Lung Cancer Screening Rates Remain Low Despite USPSTF Recommendations

Only 262,700 of the eligible 6.8 million smokers or ex-smokers underwent LDCT in 2015.

NSCLC: Etoposide/Cisplatin May Be Superior to Carboplatin/Paclitaxel With Radiation

NSCLC: Etoposide/Cisplatin May Be Superior to Carboplatin/Paclitaxel With Radiation

Chemoradiotherapy with etoposide plus cisplatin may improve overall survival over weekly paclitaxel plus carboplatin.

Adding Bevacizumab to Standard Chemotherapy in Extensive-disease SCLC

Adding Bevacizumab to Standard Chemotherapy in Extensive-disease SCLC

Adding bevacizumab to both for the first-line treatment of extensive-disease small cell lung cancer (SCLC) improved progression-free survival, but not overall survival.

Stereotactic Radiosurgery Recommended as Initial Treatment in Brain-metastatic NSCLC

Stereotactic Radiosurgery Recommended as Initial Treatment in Brain-metastatic NSCLC

Stereotactic radiosurgery followed by erlotinib is efficacious for treating patients with non-small cell lung cancer (NSCLC).

Does Race Determine Genomic Aberrations in Lung Tumors?

Does Race Determine Genomic Aberrations in Lung Tumors?

Being of African American or Caucasian descent does not determine the likelihood of genomic mutations in a lung tumor.

NSCLC: Cardiotoxicity Common After High-dose Thoracic Radiotherapy

NSCLC: Cardiotoxicity Common After High-dose Thoracic Radiotherapy

Cardiac events were relatively common following high-dose thoracic radiotherapy among patients with stage III non-small cell lung cancer (NSCLC).

Proportion of Untreated Stage III-IV Lung Cancers Increasing

Proportion of Untreated Stage III-IV Lung Cancers Increasing

The proportion of patients with untreated stage IIIA or IV non-small cell lung cancer (NSCLC) is rising despite superior outcomes.

Lung Cancer Risk Assessment Should Include Lung Function Assessment

Lung Cancer Risk Assessment Should Include Lung Function Assessment

Lung cancer screening programs may be improved with the use of risk prediction models that incorporate lung function.

FDA Grants Priority Review to Pembrolizumab + Chemo sBLA for NSCLC

FDA Grants Priority Review to Pembrolizumab + Chemo sBLA for NSCLC

The FDA has granted Priority Review to Merck's sBLA for pembrolizumab (Keytruda) in combination with chemotherapy.

Chemotherapy in Lung Cancer: Evaluating Timing for Adjuvant Treatment

Chemotherapy in Lung Cancer: Evaluating Timing for Adjuvant Treatment

Timing of adjuvant chemotherapy after a patient undergoes resection for non-small cell lung cancer (NSCLC) may be a factor of overall survival.

Nivolumab Shows Encouraging Survival Rates in Recurrent SCLC

Nivolumab Shows Encouraging Survival Rates in Recurrent SCLC

Nivolumab monotherapy and combined with ipilimumab shows encouraging response among patients with small cell lung cancer (SCLC).

Efficacy of Cisplatin Etoposide and Carboplatin Paclitaxel for NSCLC

Efficacy of Cisplatin Etoposide and Carboplatin Paclitaxel for NSCLC

For patients being treated for stage 3 NSCLC, cisplatin-etoposide or carboplatin-paclitaxel demonstrate comparable efficacy.

Rovalpituzumab Tesirine Active in Recurrent Small Cell Lung Cancer

Rovalpituzumab Tesirine Active in Recurrent Small Cell Lung Cancer

Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable toxicity profile.

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters